ACR GUIDELINES Bundle (free trial)

Acute Gout

American College of Rheumatology GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/631806

Contents of this Issue

Navigation

Page 2 of 5

Treatment 3 Figure 1. Management of an Acute Gout Attack General Principles: • Acute gouty arthritis attacks should be treated with pharmacologic therapy. (C) • To provide optimal care, pharmacologic treatment should be initiated within 24 hours of acute gout attack onset. (C) • Ongoing pharmacologic ULT should not be interrupted during an acute gout attack. (C) Mild-Moderate Pain, particularly for an attack affecting only 1 or a few small joints or 1–2 large joints NSAID (A) ( a or COX-2 inhibitor) Systemic Corticosteroids (A) Supplement with Topical Ice as needed (B) Colchicine b (A) Patient Education: including diet and lifestyle; role of uric acid excess in gout and as key treatment target; prompt self-treatment of subsequent acute gout attacks (B) Consider indications for ULT or adjustment of ongoing ULT (See Gout Managing Hyperuricemia Pocket Card) (C) Monotherapy (A) Option: Initial combination therapy (See Table 2) (C) Inadequate Response c Successful Outcome Switch to alternate monotherapy (C) Option: Add-on combination therapy (C) (See Table 2) Inadequate Response c Off-Label Therapies in Development d a Selective COX-2 inhibition with agents available outside the USA such as etoricoxib (A) was recommended as an option in patients with GI contra-indications or intolerance to NSAIDs, but selective COX-2 inhibition shares many adverse events with NSAID therapy. COX-2 inhibition therapy with celecoxib (B) requires high doses and has an unclear risk-benefit ratio at this time. b Colchicine was recommended as an appropriate option for acute gout if started within 36 hours of symptom onset. c Inadequate response is defined as: <20% improvement in pain score within 24 hours or <50% at ≥24 hours d Off-label use of biologic IL-1 inhibitor treatment has been investigated for acute gout when non-biologic therapeutic categories are ineffective or contraindicated, but this approach is not approved for gout by medical regulatory agencies at the time this is written. Assess Severity Severe Pain, particularly for a polyarticular attack or an attack affecting multiple large joints

Articles in this issue

Archives of this issue

view archives of ACR GUIDELINES Bundle (free trial) - Acute Gout